{"url_path":"/sec/bbio/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-027445-index.html","accession_number":"0001140361-26-027445","cik":"0001743881","ticker":"BBIO","issuer_name":"BridgeBio Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-027445-index.html","primary_entity_key":"0001743881","primary_entity_name":"BridgeBio Pharma, Inc."},"word_count":207,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n \n\n(d) Exhibits\n\nExhibit\n\nNumber\n\n \n\nDescription\n\n \n\n \n\n \n\n[3.1](ef20077282_ex3-1.htm)\n\n \n\nCertificate of Designations, Preferences and Rights of Series A Cumulative Convertible Participating Preferred Stock of BridgeBio Pharma, Inc.\n\n \n\n \n\n \n\n[10.1*†](ef20077282_ex10-1.htm)\n\n \n\nInvestment Agreement, dated as of July 1, 2026, by and among BridgeBio Pharma, Inc. and the Purchasers identified therein.\n\n \n\n \n\n \n\n[10.2*](ef20077282_ex10-2.htm)\n\n \n\nRegistration Rights Agreement, dated as of July 1, 2026, by and among BridgeBio Pharma, Inc. and the Purchasers identified therein.\n\n \n\n \n\n \n\n[99.1](ef20077282_ex99-1.htm)\n\n \n\nPress Release of BridgeBio Pharma, Inc., dated July 1, 2026.\n\n \n\n \n\n \n\n104\n\n \n\nCover page interactive data file (embedded within the inline XBRL document).\n\n*Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5).\n\n †Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission because such\ninformation (i) is not material and (ii) is the type that the registrant treats as private or confidential.\n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\n \n\n \n\n \n\nBridgeBio Pharma, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJuly 2, 2026\n\nBy:\n\n/s/ Neil Kumar\n\n \n\n \n\n \n\nName: Neil Kumar\n\nTitle: Chief Executive Officer"}